LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK1059615 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4469 | 4223 | 1.0583 | 1.0873 |
| SK-BR-3 | GSK1059615 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3841 | 4223 | 0.9096 | 0.8647 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3338 | 4223 | 0.7906 | 0.6866 |
| SK-BR-3 | Omipalisib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1406 | 4223 | 0.3330 | 0.0017 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3111 | 4223 | 0.7367 | 0.6059 |
| SK-BR-3 | GW843682X | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3654 | 4223 | 0.8653 | 0.7984 |
| SK-BR-3 | HG-5-113-01 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3952 | 4223 | 0.9358 | 0.9039 |
| SK-BR-3 | HG-5-88-01 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3097 | 4223 | 0.7334 | 0.6009 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4418 | 4223 | 1.0462 | 1.0691 |
| SK-BR-3 | JNK-9L | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3296 | 4223 | 0.7806 | 0.6717 |
| SK-BR-3 | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3052 | 4223 | 0.7229 | 0.5852 |
| SK-BR-3 | Lapatinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1652 | 4223 | 0.3913 | 0.0890 |
| SK-BR-3 | LDN-193189 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4952 | 4223 | 1.1728 | 1.2586 |
| SK-BR-3 | Linifanib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4563 | 4223 | 1.0806 | 1.1207 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3831 | 4223 | 0.9072 | 0.8610 |
| SK-BR-3 | Mitoxantrone | 0.04 | uM | LJP5 | 72 | hr | 1401 | 1595 | 4223 | 0.3778 | 0.0688 |
| SK-BR-3 | Mitoxantrone | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1585 | 4223 | 0.3753 | 0.0650 |
| SK-BR-3 | MK2206 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3077 | 4223 | 0.7288 | 0.5941 |
| SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 1538 | 4223 | 0.3642 | 0.0484 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4725 | 4223 | 1.1190 | 1.1781 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4432 | 4223 | 1.0495 | 1.0740 |
| SK-BR-3 | NU7441 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4400 | 4223 | 1.0419 | 1.0627 |
| SK-BR-3 | Dactolisib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 1558 | 4223 | 0.3689 | 0.0555 |
| SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4262 | 4223 | 1.0093 | 1.0139 |
| SK-BR-3 | Palbociclib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3204 | 4223 | 0.7588 | 0.6391 |